Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope

Journal of Immunology

Volumn 177, Issue 1, 2006, Pages 255-267

  Ryan, Christina M ^a   Schell, Todd D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; VIRUS LARGE T ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CD8+ T LYMPHOCYTE; CHOROID PLEXUS TUMOR; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH;

EID: 33745315818     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.1.255     Document Type: Article

References (71)

1. Melief, C. J., R. E. Toes, J. P. Medema, S. H. van der Burg, F. Ossendorp, and R. Offringa. 2000. Strategies for immunotherapy of cancer. Adv. Immunol. 75: 235-282.
2. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281-355.
3. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16: 323-358.
4. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183: 725-729.
5. Stockinger, B. 1999. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv. Immunol. 71: 229-265.
6. Ashton-Rickardt, P. G., A. Bandeira, J. R. Delaney, L. Van Kaer, H. P. Pircher, R. M. Zinkernagel, and S. Tonegawa. 1994. Evidence for a differential avidity model of T cell selection in the thymus. Cell 76: 651-663.
7. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88.
8. Urban, J. L., C. Van Waes, and H. Schreiber. 1984. Pecking order among tumor-specific antigens. Eur. J. Immunol. 14: 181-187.
9. b-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology 171: 205-213.
10. Lotz, C., E. A. Ferreira, I. Drexler, S. A. Mutallib, C. Huber, G. Sutter, and M. Theobald. 2004. Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man. Int. J. Cancer 108: 571-579.
11. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185: 833-841.
12. Friedman, R. S., A. G. Spies, and M. Kalos. 2004. Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. Eur. J. Immunol. 34: 1091-1101.
13. d-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection. Virology 244: 427-441.
14. Duraiswamy, J., M. Bharadwaj, J. Tellam, G. Connolly, L. Cooper, D. Moss, S. Thomson, P. Yotnda, and R. Khanna. 2004. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res. 64: 1483-1489.
15. Feltkamp, M. C. W., G. R. Vreugdenhil, M. P. M. Vierboom, E. Ras, S. H. van der Burg, J. ter Schegget, C. J. M. Melief, and W. M. Kast. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25: 2638-2642.
16. Grossmann, M. E., E. Davila, and E. Celis. 2001. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J. Immunother. 24: 237-241.
17. + T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. J. Virol. 78: 1751-1762.
18. Schell, T. D., B. B. Knowles, and S. S. Tevethia. 2000. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res. 60: 3002-3012.
19. Palmiter, R. D., H. Y. Chen, A. Messing, and R. L. Brinster. 1985. SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumors in transgenic mice. Nature 316: 457-460.
20. Van Dyke, T. A., C. Finlay, D. Miller, J. Marks, G. Lozano, and A. J. Levine. 1987. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J. Virol. 61: 2029-2032.
21. b-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. J. Virol. 66: 440-447.
22. b-restricted cytotoxic T lymphocyte epitopes in simian virus 40 tumor antigen. J. Virol. 69: 3134-3146.
23. b-restricted determinant in simian virus 40 tumor antigen. Virology 208: 159-172.
24. Fu, T.-M., L. M. Mylin, T. D. Schell, I. Bacik, O. Russ, J. W. Yewdell, J. R. Bennink, and S. S. Tevethia. 1998. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J. Virol. 72: 1469-1481.
25. b-restricted cytotoxic T lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69: 6665-6677.
26. Schell, T. D., L. M. Mylin, I. Georgoff, A. K. Teresky, A. J. Levine, and S. S. Tevethia. 1999. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J. Virol. 73: 5981-5993.
27. + T cell response to a subdominant tumor antigen epitope. J. Immunol. 175: 700-712.
28. + T-cell/dendritic cell interactions in vivo. Cell. Immunol. 214: 110-122.
29. + T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J. Virol. 74: 6922-6934.
30. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290-296.
31. + T lymphocytes by the endogenous tumor antigen. J. Immunol. 167: 6947-6956.
32. Cserr, H. F., and P. M. Knopf. 1992. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 13: 507-512.
33. Masopust, D., and R. Ahmed. 2004. Reflections on CD8 T-cell activation and memory. Immunol. Res. 29: 151-160.
34. + T cells in tumor-bearing mice. J. Immunol. 174: 2563-2572.
35. + T cells. J. Exp. Med. 186: 239-245.
36. Robbins, P. F., M. E. Dudley, J. Wunderlich, M. El-Gamil, Y. F. Li, J. Zhou, J. Huang, D. J. Powell, Jr., and S. A. Rosenberg. 2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173: 7125-7130.
37. + T cells upon in vivo stimulation with allogeneic tumor. J. Immunol. 159: 650-663.
38. Yu, P., Y. Lee, W. Liu, R. K. Chin, J. Wang, Y. Wang, A. Schietinger, M. Philip, H. Schreiber, and Y. X. Fu. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5: 141-149.
39. Yu, R., K. Fujio, H. Tahara, Y. Araki, and K. Yamamoto. 2005. Clonal dynamics of tumor-infiltrating lymphocytes. Eur. J. Immunol. 35: 1754-1763.
40. Blohm, U., E. Roth, K. Brommer, T. Dumrese, F. M. Rosenthal, and H. Pircher. 2002. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J. Immunol. 169: 5522-5530.
41. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5: 677-685.
42. Drake, C. G., A. D. Doody, M. A. Mihalyo, C. T. Huang, E. Kelleher, S. Ravi, E. L. Hipkiss, D. B. Flies, E. P. Kennedy, M. Long, et al. 2005. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7: 239-249.
43. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
44. Okano, F., M. Merad, K. Furumoto, and E. G. Engleman. 2005. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. J. Immunol. 174: 2645-2652.
45. Ercolini, A. M., J. P. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee. 2003. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 170: 4273-4280.
46. Doan, T., K. Herd, M. Street, O. Bryson, O. Fernando, P. Lambert, and R. Tindle. 1999. Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J. Virol. 73: 6166-6170.
47. + T cells. J. Exp. Med. 198: 569-580.
48. Colella, T. A., T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191: 1221-1232.
49. Cordaro, T. A., K. E. de Visser, F. H. Tirion, T. N. Schumacher, and A. M. Kruisbeek. 2002. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J. Immunol 168: 651-660.
50. de Visser, K. E., T. A. Cordaro, H. W. Kessels, F. H. Tirion, T. N. Schumacher, and A. M. Kruisbeek. 2001. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J. Immunol 167: 3818-3828.
51. Doan, T., M. Chambers, M. Street, G. J. Fernando, K. Herd, P. Lambert, and R. Tindle. 1998. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology 244: 352-364.
52. Makki, A., G. Weidt, N. E. Blachere, L. Lefrancois, and P. K. Srivastava. 2002. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun. 2: 4.
53. + cytolytic T lymphocytes. J. Exp. Med. 183: 791-800.
54. Singh, R., M. E. Dominiecki, E. M. Jaffee, and Y. Paterson. 2005. Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol. 175: 3663-3673.
55. van Stipdonk, M. J., E. E. Lemmens, and S. P. Schoenberger. 2001. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol. 1: 423-429.
56. Plautz, G. E., J. E. Touhalisky, and S. Shu. 1997. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell. Immunol 178: 101-107.
57. + T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol 166: 2863-2870.
58. Tanchot, C., and B. Rocha. 1997. Peripheral selection of T cell repertoires: the role of continuous thymus output. J. Exp. Med. 186: 1099-1106.
59. Koido, S., Y. Tanaka, D. Chen, D. Kufe, and J. Gong. 2002. The kinetics of in vivo priming of CD4 and CD8 T cells by dendriticJtumor fusion cells in MUC1-transgenic mice. J. Immunol. 168: 2111-2117.
60. + T cell responses. Eur. J. Immunol. 35: 2532-2540.
61. Feuerer, M., P. Beckhove, N. Garbi, Y. Mahnke, A. Limmer, M. Hommel, G. J. Hammerling, B. Kyewski, A. Hamann, V. Umansky, and V. Schirrmacher. 2003. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat. Med. 9: 1151-1157.
62. Randolph, G. J., V. Angeli, and M. A. Swartz. 2005. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5: 617-628.
63. Riley, J. L., and C. H. June. 2005. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105: 13-21.
64. Gett, A. V., F. Sallusto, A. Lanzavecchia, and J. Geginat. 2003. T cell fitness determined by signal strength. Nat. Immunol. 4: 355-360.
65. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64.
66. Onami, T. M., L. E. Harrington, M. A. Williams, M. Galvan, C. P. Larsen, T. C. Pearson, N. Manjunath, L. G. Baum, B. D. Pearce, and R. Ahmed. 2002. Dynamic regulation of T cell immunity by CD43. J. Immunol. 168: 6022-6031.
67. Hickey, W. F., B. L. Hsu, and H. Kimura. 1991. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28: 254-260.
68. Fabry, Z., M. M. Waldschmidt, D. Hendrickson, J. Keiner, L. Love-Homan, F. Takei, and M. N. Hart. 1992. Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55.7. Neuroimmunol. 36: 1-11.
69. Auphan-Anezin, N., G. Verdeil, and A. M. Schmitt-Verhulst. 2003. Distinct thresholds for CD8 T cell activation lead to functional heterogeneity: CD8 T cell priming can occur independently of cell division. J. Immunol. 170: 2442-2448.
70. Khong, H. T., and N. P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3: 999-1005.
71. Roy, E. J., U. Gawlick, B. A. Orr, L. A. Rund, A. G. Webb, and D. M. Kranz. 2000. IL-12 treatment of endogenously arising murine brain tumors. J. Immunol. 165: 7293-7299.